Drugs and Valvular Heart Disease
Published January 4, 2007
N Engl J Med 2007;356:6-9
DOI: 10.1056/NEJMp068265
Abstract
In 1997, Connolly et al. reported that both racemic fenfluramine (Pondimin) and dexfenfluramine (Redux) were associated with valvular heart disease.1 The valvular abnormalities seen in patients treated with these agents were distinctive. On echocardiography, leaflet thickening as well as chordal thickening and retraction were observed. Surgically removed valves were noted to have a glistening white surface, with histologic evidence of a plaque-like process extending along the leaflet surfaces and encasing the chordae tendineae. These findings were similar to those in patients with heart-valve damage induced by serotonin-secreting carcinoid tumors.1
This association of racemic fenfluramine and dexfenfluramine with valvular heart disease . . .
Information & Authors
Information
Published In
Copyright
Copyright © 2007 Massachusetts Medical Society. All rights reserved.
For personal use only. Any commercial reuse of NEJM Group content requires permission.
History
Published online: January 4, 2007
Published in issue: January 4, 2007
Topics
Authors
Affiliations
Dr. Roth is a professor in the Departments of Pharmacology and Medicinal Chemistry, Schools of Medicine and Pharmacy, and director of the National Institute of Mental Health Psychoactive Drug Screening Program at the University of North Carolina, Chapel Hill.
Metrics & Citations
Metrics
Altmetrics
Citations
Export citation
Select the format you want to export the citation of this publication.
Cited by
- Debate: Surgery as Initial Therapy for Microprolactinoma, The Journal of Clinical Endocrinology & Metabolism, (2025).https://doi.org/10.1210/clinem/dgaf434
- The polypharmacology of psychedelics reveals multiple targets for potential therapeutics, Neuron, 113, 19, (3129-3142.e9), (2025).https://doi.org/10.1016/j.neuron.2025.06.012
- Artificial Intelligence in Cardiovascular Diseases, Artificial Intelligence in Human Health and Diseases, (171-203), (2025).https://doi.org/10.1007/978-981-96-8176-1_10
- Cardiovascular effects and safety of classic psychedelics, Nature Cardiovascular Research, 4, 2, (131-144), (2025).https://doi.org/10.1038/s44161-025-00608-2
- Outcomes in surgical management of microprolactinomas: an international multi-institutional series, Pituitary, 28, 1, (2025).https://doi.org/10.1007/s11102-025-01497-1
- Clinical pharmacology, Psychedelics in Psychiatry, (99-148), (2025).https://doi.org/10.1016/bs.irn.2025.02.003
- Dopamine receptor drugs and their applications, The Handbook of Dopamine, (171-186), (2025).https://doi.org/10.1016/B978-0-443-29867-7.00013-X
- Medical therapy of pituitary adenomas, Brain Medicine, (1-9), (2024).https://doi.org/10.61373/bm024i.0127
- The effect of cancer-associated mutations on ligand binding and receptor function – A case for the 5-HT2C receptor, European Journal of Pharmacology, 985, (177081), (2024).https://doi.org/10.1016/j.ejphar.2024.177081
- Dihydroergotamine for migraine: Evidence for multiple modes of action: The single molecule ‘combination’ product—A narrative review, Cephalalgia Reports, 7, (2024).https://doi.org/10.1177/25158163241292297
- See more
Loading...